• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Invivyd, Inc. - Common Stock (NQ:IVVD)

    0.6103 +0.0283 (+4.86%)
    Delayed Quote Updated: 11:03 AM EST, Nov 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Invivyd, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Invivyd, Inc.
    Via GlobeNewswire
    News headline image
    Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
    From Invivyd, Inc.
    Via GlobeNewswire
    News headline image
    Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
    From Invivyd, Inc.
    Via GlobeNewswire
    News headline image
    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Invivyd, Inc.
    Via GlobeNewswire
    News headline image
    Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
    From Invivyd, Inc.
    Via GlobeNewswire
    News headline image
    Invivyd to Participate in Upcoming September Investor Conferences
    From Invivyd, Inc.
    Via GlobeNewswire
    News headline image
    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd to Participate in Upcoming Investor Events
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Presentation at the World Vaccine Congress Washington
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Invivyd
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.